Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rubius gets $120mm in second financing

Executive Summary

In what appears to be its Series B round, cell therapies developer Rubius Therapeutics Inc. raised $120mm in a highly oversubscribed private financing to 16 investors. The company will use the funds for ongoing development of its Red-Cell Therapeutics, a new class of compounds with potential for treating cancer, autoimmune disease, hemophilia, infectious diseases, and metabolic disorders. Clinical trials should commence in 2018. It will also use some money to expand its team.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies